A new resource is now available to download for free. MASLD drug development is limited by models that don’t reflect human liver biology. HUB’s patient-derived liver organoids retain donor genetics, architecture and physiology. Download the Factsheet to learn: How organoids recapitulate steatosis and fibrosis Which readouts support target validation… Read More
Daniel Delubac, Chief Executive Officer at iOrganBio looks at how technologies that mimic human behaviour can improve drug discovery efforts past animal models. The US is signalling a decisive shift toward human-based drug discovery. In March, the National Institutes… Read More
CN Bio, a provider of organ-on-a-chip (OOC) systems, has been awarded £180k ($243k) grant funding from Innovate UK. Delivered in partnership with the National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs), the funding aims to support new approach methodologies (NAMs) for… Read More
Daniel Delubac, Chief Executive Officer at iOrganBio, looks at how technologies that mimic human behaviour can improve drug discovery efforts past animal models. The US is signalling a decisive shift toward human-based drug discovery. In March, the National Institutes of Health… Read More
By Carolina Lucchesi, Principal Scientist and Head of Microphysiological Systems, ATCC. Across the world, regulators are sending a consistent signal: the era of animal-only preclinical testing is drawing to a close. In the United States, the Food and Drug Administration (FDA) has committed to phasing out animal testing requirements1. The European Union and United Kingdom are moving in the… Read More
Professor Mark Lewis, CEO of Myomaker Bio explores how animal testing is being reduced through a new era of drug development. Across the world, there is growing evidence that the long-standing reliance on animal testing in scientific research could be entering a period of significant change. For decades, scientists, regulators and… Read More
The Medicines and Healthcare products Regulatory Agency (MHRA) will offer early review of non-animal data in a decision supporting the government’s strategy to reduce animal testing in drug development. The move is intended to help drug developers make greater use of New Approach Methodologies (NAMs), hopefully giving developers… Read More
Researchers at the Francis Crick Institute and AlveoliX have developed the first human ‘lung-on-chip’ model using stem cells taken from only one person. These chips simulate breathing motions and lung disease in an individual, holding promise for testing treatments for infections like tuberculosis (TB) and delivering personalised… Read More
A new US Standardized Organoid Modeling (SOM) Center will be dedicated to using cutting-edge technologies to develop standardised organoid-based new approach methodologies (NAMs). With contracts totalling $87 million for the first three years, the centre will be housed at the Frederick National Laboratory for Cancer Research (FNLCR),… Read More
